Literature DB >> 18762368

S100P sensitizes ovarian cancer cells to carboplatin and paclitaxel in vitro.

Qi Wang1, Zhijuan He, Jianhua Gao, Shuangjiu Hu, Mingli Huang, Min Liu, Jianhua Zheng, Hua Tang.   

Abstract

OBJECTIVE: To investigate the relationship between the S100P and the sensitivity of ovarian cancer to chemotherapeutics.
METHOD: We established stable cell lines of ovarian cancer cells, SKOV3 and OVCAR3, that overexpress human S100P. We also transiently transfected the parent cell lines with S100P-targeted siRNA for down-regulation of S100P expression. The sensitivity of all transfected and untransfected cell lines to carboplatin and paclitaxel was detected by MTT assay.
RESULTS: For both cells, IC50s decreased to carboplatin and paclitaxel (p<0.05), with overexpression of S100P compared to untransfected cells. Alternatively, with down-regulation of S100P by siRNA, the IC50 to carboplatin and paclitaxel increased in each case (p<0.05), which was significantly higher compared to untransfected cells.
CONCLUSION: Changes in expression levels of S100P in SKOV3 and OVCAR3 cells results in variable susceptibility to carboplatin and paclitaxel. These data suggest that S100P contributes to chemosensitivity to carboplatin and paclitaxel in ovarian cancer cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18762368     DOI: 10.1016/j.canlet.2008.07.017

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

Review 1.  Calcium-binding protein S100P and cancer: mechanisms and clinical relevance.

Authors:  Hongfei Jiang; Hang Hu; Xiaomei Tong; Qiuhong Jiang; Haiyan Zhu; Songying Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-24       Impact factor: 4.553

2.  High expression of S100P is associated with unfavorable prognosis and tumor progression in patients with epithelial ovarian cancer.

Authors:  Xiangyu Wang; Tian Tian; Xukun Li; Meng Zhao; Yanhui Lou; Jingfeng Qian; Zhihua Liu; Hongyan Chen; Zhumei Cui
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

3.  A quantitative proteomics-based signature of platinum sensitivity in ovarian cancer cell lines.

Authors:  Gaofeng Fan; Kazimierz O Wrzeszczynski; Cexiong Fu; Gang Su; Darryl J Pappin; Robert Lucito; Nicholas K Tonks
Journal:  Biochem J       Date:  2015-02-01       Impact factor: 3.857

4.  Calcium-Binding Protein S100P Promotes Tumor Progression but Enhances Chemosensitivity in Breast Cancer.

Authors:  Yizi Cong; Yuxin Cui; Suxia Wang; Lei Jiang; Jianqiao Cao; Shiguang Zhu; Emily Birkin; Jane Lane; Fiona Ruge; Wen G Jiang; Guangdong Qiao
Journal:  Front Oncol       Date:  2020-09-15       Impact factor: 6.244

5.  Effect of STK17A on the sensitivity of ovarian cancer cells to paclitaxel and carboplatin.

Authors:  Jianhua Gao; Dan Liu; Jie Li; Qianlin Song; Qi Wang
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

6.  Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.

Authors:  Jin Song; Ie-ming Shih; Daniel W Chan; Zhen Zhang
Journal:  Neoplasia       Date:  2009-06       Impact factor: 5.715

Review 7.  The life and works of S100P - from conception to cancer.

Authors:  Filip Prica; Tomasz Radon; Yuzhu Cheng; Tatjana Crnogorac-Jurcevic
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

8.  Cancer-associated S100P protein binds and inactivates p53, permits therapy-induced senescence and supports chemoresistance.

Authors:  Adriana Gibadulinova; Michal Pastorek; Pavel Filipcik; Peter Radvak; Lucia Csaderova; Borivoj Vojtesek; Silvia Pastorekova
Journal:  Oncotarget       Date:  2016-04-19

9.  The Aminosteroid Derivative RM-133 Shows In Vitro and In Vivo Antitumor Activity in Human Ovarian and Pancreatic Cancers.

Authors:  Lucie Carolle Kenmogne; Diana Ayan; Jenny Roy; René Maltais; Donald Poirier
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.